• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-1、PD-L1和PD-L2在小鼠前列腺癌中的表达

PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.

作者信息

Yang Shijie, Zhang Qiuyang, Liu Sen, Wang Alun R, You Zongbing

机构信息

Department of Structural and Cellular Biology, Tulane UniversityNew Orleans, LA, USA; Department of Urology, The Third Hospital of Hebei Medical UniversityShijiazhuang, China.

Department of Structural and Cellular Biology, Tulane University New Orleans, LA, USA.

出版信息

Am J Clin Exp Urol. 2016 Jan 28;4(1):1-8. eCollection 2016.

PMID:27069956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4749401/
Abstract

Programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2 play critical roles in maintaining an immunosuppressive tumor microenvironment. The purpose of the present study was to assess expression of PD-1, PD-L1, and PD-L2 in mouse prostate tumors. A total of 33 mouse prostate tumors derived from Pten-null mice were examined using immunohistochemical staining for PD-1, PD-L1, and PD-L2. The animals were either with interleukin-17 receptor c (Il-17rc) wild-type or knockout genotype, or fed with regular diet or high-fat diet to 30 weeks of age. We found that Il-17rc wild-type mouse prostate tumors had significantly higher levels of PD-1, PD-L1, and PD-L2 than Il-17rc knockout mouse prostate tumors. High-fat diet-induced obese mice had significantly higher levels of PD-1, PD-L1, and PD-L2 in their prostate tumors than lean mice fed with regular diet. Increased expression of PD-1, PD-L1, and PD-L2 was associated with increased number of invasive prostate tumors formed in the Il-17rc wild-type and obese mice compared to the Il-17rc knockout and lean mice, respectively. Our findings suggest that expression of PD-1, PD-L1, and PD-L2 may enhance development of mouse prostate cancer through creating an immunosuppressive tumor microenvironment.

摘要

程序性细胞死亡蛋白1(PD-1)及其配体PD-L1和PD-L2在维持免疫抑制性肿瘤微环境中发挥着关键作用。本研究的目的是评估PD-1、PD-L1和PD-L2在小鼠前列腺肿瘤中的表达情况。使用针对PD-1、PD-L1和PD-L2的免疫组织化学染色检查了总共33个源自Pten基因缺失小鼠的小鼠前列腺肿瘤。这些动物要么具有白细胞介素-17受体c(Il-17rc)野生型或敲除基因型,要么喂食常规饮食或高脂饮食至30周龄。我们发现,Il-17rc野生型小鼠前列腺肿瘤中PD-1、PD-L1和PD-L2的水平显著高于Il-17rc敲除小鼠前列腺肿瘤。高脂饮食诱导的肥胖小鼠前列腺肿瘤中PD-1、PD-L1和PD-L2的水平显著高于喂食常规饮食的瘦小鼠。与Il-17rc敲除小鼠和瘦小鼠相比,Il-17rc野生型小鼠和肥胖小鼠中PD-1、PD-L1和PD-L2表达的增加分别与侵袭性前列腺肿瘤形成数量的增加有关。我们的研究结果表明,PD-1、PD-L1和PD-L2的表达可能通过创造免疫抑制性肿瘤微环境来促进小鼠前列腺癌的发展。

相似文献

1
PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.PD-1、PD-L1和PD-L2在小鼠前列腺癌中的表达
Am J Clin Exp Urol. 2016 Jan 28;4(1):1-8. eCollection 2016.
2
A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction.程序性细胞死亡受体配体 2 在脓毒症诱导的肝损伤中的新作用。
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G106-G114. doi: 10.1152/ajpgi.00204.2018. Epub 2018 Nov 15.
3
Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.炎性细胞因子白细胞介素-17(IL-17)和肿瘤坏死因子-α(TNF-α)上调人前列腺癌细胞和结肠癌细胞中程序性死亡受体配体1(PD-L1)的表达。
Immunol Lett. 2017 Apr;184:7-14. doi: 10.1016/j.imlet.2017.02.006. Epub 2017 Feb 14.
4
Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.程序性死亡1配体(PD-L)1和PD-L2限制自身免疫性肾脏疾病:不同作用。
J Immunol. 2007 Dec 1;179(11):7466-77. doi: 10.4049/jimmunol.179.11.7466.
5
Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.白细胞介素-17 通过诱导免疫耐受和促进血管生成促进去势抵抗性前列腺癌的发展。
Prostate. 2014 Jun;74(8):869-79. doi: 10.1002/pros.22805. Epub 2014 Apr 1.
6
Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.程序性死亡 1 及其配体在自身免疫性肝炎 C57BL/6 小鼠肝脏中的表达。
Chin Med J (Engl). 2009 Aug 20;122(16):1941-6.
7
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.程序性细胞死亡配体在肝细胞癌中的表达:与免疫微环境及生存结果的相关性
Front Oncol. 2019 Sep 11;9:883. doi: 10.3389/fonc.2019.00883. eCollection 2019.
8
Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.免疫调节分子 PD-1、PD-L1 和 PD-L2 的表达及其与子宫内膜癌临床病理特征的关系。
Int J Gynecol Pathol. 2019 Sep;38(5):404-413. doi: 10.1097/PGP.0000000000000543.
9
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.肺鳞状细胞癌中PD-L1和PD-L2表达的临床病理分析:与肿瘤浸润性T细胞及致癌驱动因素状态的比较
Lung Cancer. 2015 Apr;88(1):24-33. doi: 10.1016/j.lungcan.2015.01.016. Epub 2015 Jan 24.
10
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.PD-L2介导的免疫抑制对自发性及治疗相关抗肿瘤免疫的作用
Clin Cancer Res. 2019 Aug 1;25(15):4808-4819. doi: 10.1158/1078-0432.CCR-18-3991. Epub 2019 May 10.

引用本文的文献

1
Murine Models of Obesity-Related Cancer Risk.肥胖相关癌症风险的小鼠模型
Cancer Prev Res (Phila). 2025 Jun 13. doi: 10.1158/1940-6207.CAPR-24-0545.
2
Contemporaneous and upcoming trends in immunotherapy for prostate cancer: review.前列腺癌免疫治疗的当前及未来趋势:综述
Ann Med Surg (Lond). 2023 Jul 7;85(8):4005-4014. doi: 10.1097/MS9.0000000000001070. eCollection 2023 Aug.
3
Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer.度伐利尤单抗:一种 PD-1/PD-L1 抑制剂:癌症治疗的新模式。
Medicina (Kaunas). 2022 Nov 1;58(11):1572. doi: 10.3390/medicina58111572.
4
The role of obesity and bariatric surgery-induced weight loss in breast cancer.肥胖和减重手术在乳腺癌中的作用。
Cancer Metastasis Rev. 2022 Sep;41(3):673-695. doi: 10.1007/s10555-022-10050-6. Epub 2022 Jul 23.
5
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, , , and Other Genes.关于前列腺癌中PD-L1表达我们需要了解什么?一项系统文献综述(第6部分):PD-L1表达与错配修复系统状态及其他基因的相关性
Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
6
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.关于前列腺癌中PD-L1表达我们需要了解什么?一项系统文献综述。第7部分:液体活检中的PD-L1表达
J Pers Med. 2021 Dec 6;11(12):1312. doi: 10.3390/jpm11121312.
7
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.我们需要了解前列腺癌中 PD-L1 表达的哪些方面?系统文献综述。第 1 部分:重点关注免疫组织化学结果,并讨论分析前和解释变量。
Cells. 2021 Nov 14;10(11):3166. doi: 10.3390/cells10113166.
8
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.前列腺癌中 PD-L1 表达我们需要了解什么?系统文献回顾。第 2 部分:临床-病理相关性。
Cells. 2021 Nov 14;10(11):3165. doi: 10.3390/cells10113165.
9
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.我们需要了解前列腺癌中 PD-L1 表达的哪些信息?系统文献回顾。第 3 部分:PD-L1、细胞内信号通路和肿瘤微环境。
Int J Mol Sci. 2021 Nov 15;22(22):12330. doi: 10.3390/ijms222212330.
10
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.关于前列腺癌中程序性死亡受体配体1(PD-L1)表达我们需要了解什么?一项系统文献综述。第5部分:PD-L1的表观遗传调控
Int J Mol Sci. 2021 Nov 15;22(22):12314. doi: 10.3390/ijms222212314.

本文引用的文献

1
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.前列腺癌中PD-L1表达缺失:先天性和适应性免疫抵抗
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32. doi: 10.1038/pcan.2015.39. Epub 2015 Aug 11.
2
PD-L1 inhibition with MPDL3280A for solid tumors.使用MPDL3280A抑制程序性死亡受体1配体1(PD-L1)治疗实体瘤。
Semin Oncol. 2015 Jun;42(3):484-7. doi: 10.1053/j.seminoncol.2015.02.002. Epub 2015 Feb 12.
3
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
4
Pembrolizumab versus Ipilimumab in Advanced Melanoma.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤。
N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.
5
Cancer statistics, 2015.癌症统计数据,2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
6
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.程序性死亡受体配体1(PD-L1)在恩杂鲁胺耐药的前列腺癌中高表达。
Oncotarget. 2015 Jan 1;6(1):234-42. doi: 10.18632/oncotarget.2703.
7
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
8
Prostate cancer immunotherapy: beyond immunity to curability.前列腺癌免疫治疗:超越免疫到可治愈性。
Cancer Immunol Res. 2014 Nov;2(11):1034-43. doi: 10.1158/2326-6066.CIR-14-0174.
9
PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.程序性死亡蛋白1(PD-1)通路抑制剂:改变癌症免疫治疗格局
Cancer Control. 2014 Jul;21(3):231-7. doi: 10.1177/107327481402100308.
10
Tumor microenvironment and metabolism in prostate cancer.前列腺癌中的肿瘤微环境与代谢。
Semin Oncol. 2014 Apr;41(2):267-80. doi: 10.1053/j.seminoncol.2014.03.004. Epub 2014 Mar 5.